AI Summary
Balsm Alofoq will capitalize SAR 10.15 mln from share premium balance and SAR 2.35 mln from retained earnings
Balsm Alofoq Medical Co.’s shareholders approved increasing capital by 100% from SAR 12.5 million to SAR 25 million through a bonus issue, during an extraordinary general meeting (EGM) held on Dec. 21.
|
Capital Increase Details |
|
|
Current Capital |
SAR 12.50 mln |
|
Number of Shares |
1.25 mln |
|
New Capital |
SAR 25 mln |
|
New Number of Shares |
2.50 mln |
|
Percentage of Increase |
100% (one-for-one bonus issue) |
|
Reason |
To enhance the company’s strategic growth plan, meet future expansion needs and aspirations, and reinforce the company's financial viability and strong financial position |
|
Method |
By capitalizing SAR 10.15 mln from the share premium balance and SAR 2.35 mln from retained earnings |
|
Record Date |
Dec. 21, 2025 (Shareholders registered with the Securities Depository Center (Edaa) at the end of the second trading day following the record date) |
Fractional shares, if any, will be collected into one portfolio for all shareholders and sold at the market price, then their value will be distributed among eligible shareholders, on a pro rata basis, within a period not exceeding 30 days from the date of determining the shares due to each shareholder, according to the company's Tadawul statement today, Dec. 22.
In a separate statement, the Saudi Exchange (Tadawul) said that the fluctuation limits today, Dec. 22, for Balsm Alofoq will be based on a share price of SAR 27.10 and the outstanding orders will be canceled. Furthermore, the Securities Depository Center (Edaa) will deposit the addition shares into investor portfolios by Dec. 24.
Be the first to comment
Comments Analysis: